Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $357.64 | 11 | 97.0% |
| Education | $11.07 | 1 | 3.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| BIOTISSUE HOLDINGS INC. | $201.20 | 6 | $0 (2024) |
| The Walman Optical Company | $75.00 | 1 | $0 (2018) |
| Novartis Pharmaceuticals Corporation | $35.14 | 2 | $0 (2023) |
| Oyster Point Pharma, Inc. | $24.47 | 1 | $0 (2024) |
| Dompe US, Inc. | $21.83 | 1 | $0 (2019) |
| Bausch & Lomb, a division of Bausch Health US, LLC | $11.07 | 1 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $225.67 | 7 | BIOTISSUE HOLDINGS INC. ($201.20) |
| 2023 | $20.16 | 1 | Novartis Pharmaceuticals Corporation ($20.16) |
| 2022 | $14.98 | 1 | Novartis Pharmaceuticals Corporation ($14.98) |
| 2019 | $21.83 | 1 | Dompe US, Inc. ($21.83) |
| 2018 | $86.07 | 2 | The Walman Optical Company ($75.00) |
All Payment Transactions
12 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/23/2024 | BIOTISSUE HOLDINGS INC. | — | Food and Beverage | Cash or cash equivalent | $56.67 | General |
| 12/23/2024 | BIOTISSUE HOLDINGS INC. | — | Food and Beverage | Cash or cash equivalent | $23.17 | General |
| 12/23/2024 | BIOTISSUE HOLDINGS INC. | — | Food and Beverage | Cash or cash equivalent | $20.76 | General |
| 11/26/2024 | BIOTISSUE HOLDINGS INC. | — | Food and Beverage | In-kind items and services | $23.17 | General |
| 11/25/2024 | BIOTISSUE HOLDINGS INC. | — | Food and Beverage | In-kind items and services | $20.76 | General |
| 11/19/2024 | BIOTISSUE HOLDINGS INC. | — | Food and Beverage | In-kind items and services | $56.67 | General |
| 11/13/2024 | Oyster Point Pharma, Inc. | TYRVAYA (Drug), Ryzumvi | Food and Beverage | In-kind items and services | $24.47 | General |
| Category: Dry eyes | ||||||
| 02/02/2023 | Novartis Pharmaceuticals Corporation | XIIDRA (Drug) | Food and Beverage | In-kind items and services | $20.16 | General |
| Category: Ophthalmology | ||||||
| 06/28/2022 | Novartis Pharmaceuticals Corporation | XIIDRA (Drug) | Food and Beverage | In-kind items and services | $14.98 | General |
| Category: OPHTHALMOLOGY | ||||||
| 12/05/2019 | Dompe US, Inc. | Oxervate (Drug) | Food and Beverage | In-kind items and services | $21.83 | General |
| Category: Ophthalmic Solution/Drops | ||||||
| 11/08/2018 | The Walman Optical Company | — | Food and Beverage | In-kind items and services | $75.00 | General |
| 02/20/2018 | Bausch & Lomb, a division of Bausch Health US, LLC | VYZULTA (Drug) | Education | In-kind items and services | $11.07 | General |
| Category: OPHTHALMOLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 10 | 679 | 969 | $190,943 | $56,086 |
| 2022 | 10 | 611 | 872 | $170,417 | $50,431 |
| 2021 | 11 | 617 | 798 | $169,343 | $52,244 |
| 2020 | 10 | 398 | 521 | $108,866 | $30,488 |
All Medicare Procedures & Services
41 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 243 | 474 | $87,690 | $28,154 | 32.1% |
| 92014 | Established patient complete exam of visual system | Office | 2023 | 175 | 176 | $56,320 | $14,741 | 26.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 50 | 55 | $14,905 | $4,373 | 29.3% |
| 92083 | Exam of visual field with extended testing | Office | 2023 | 58 | 63 | $10,332 | $3,021 | 29.2% |
| 92133 | Imaging of optic nerve | Office | 2023 | 56 | 59 | $6,608 | $1,477 | 22.4% |
| 92004 | New patient complete exam of visual system | Office | 2023 | 13 | 13 | $4,966 | $1,077 | 21.7% |
| 83861 | Microfluid analysis of tears | Office | 2023 | 22 | 44 | $2,068 | $969.32 | 46.9% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 12 | 12 | $3,252 | $888.29 | 27.3% |
| 92134 | Imaging of retina | Office | 2023 | 28 | 29 | $3,306 | $888.20 | 26.9% |
| 83516 | Analysis of substance using immunoassay technique, multiple step method | Office | 2023 | 22 | 44 | $1,496 | $497.20 | 33.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 246 | 465 | $86,025 | $28,204 | 32.8% |
| 92014 | Established patient complete exam of visual system | Office | 2022 | 112 | 112 | $35,840 | $9,129 | 25.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 77 | 81 | $21,951 | $6,400 | 29.2% |
| 92083 | Exam of visual field with extended testing | Office | 2022 | 46 | 47 | $7,708 | $1,863 | 24.2% |
| 92004 | New patient complete exam of visual system | Office | 2022 | 12 | 12 | $4,584 | $1,313 | 28.6% |
| 92133 | Imaging of optic nerve | Office | 2022 | 54 | 55 | $6,160 | $1,267 | 20.6% |
| 83861 | Microfluid analysis of tears | Office | 2022 | 18 | 36 | $1,692 | $798.96 | 47.2% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 13 | 13 | $3,523 | $631.44 | 17.9% |
| 92134 | Imaging of retina | Office | 2022 | 15 | 15 | $1,710 | $415.26 | 24.3% |
| 83516 | Analysis of substance using immunoassay technique, multiple step method | Office | 2022 | 18 | 36 | $1,224 | $409.76 | 33.5% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 224 | 370 | $68,450 | $24,257 | 35.4% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 129 | 138 | $37,398 | $13,017 | 34.8% |
| 92014 | Eye and medical examination for diagnosis and treatment, established patient, 1 or more visits | Office | 2021 | 95 | 95 | $30,400 | $6,204 | 20.4% |
| 92083 | Measurement of field of vision during daylight conditions, extended examination | Office | 2021 | 41 | 44 | $7,216 | $2,243 | 31.1% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 15 | 15 | $6,165 | $1,674 | 27.1% |
About Dr. Dane Peterson, OD
Dr. Dane Peterson, OD is a Optometrist healthcare provider based in St. Anthony, Minnesota. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/08/2009. The National Provider Identifier (NPI) number assigned to this provider is 1285863530.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Dane Peterson, OD has received a total of $368.71 in payments from pharmaceutical and medical device companies, with $225.67 received in 2024. These payments were reported across 12 transactions from 6 companies. The most common payment nature is "Food and Beverage" ($357.64).
As a Medicare-enrolled provider, Peterson has provided services to 2,305 Medicare beneficiaries, totaling 3,160 services with total Medicare billing of $189,249. Data is available for 4 years (2020–2023), covering 41 distinct procedure/service records.
Practice Information
- Specialty Optometrist
- Other Specialties Optometrist
- Location St. Anthony, MN
- Active Since 07/08/2009
- Last Updated 03/17/2020
- Taxonomy Code 152W00000X
- Entity Type Individual
- NPI Number 1285863530
Products in Payments
- XIIDRA (Drug) $35.14
- TYRVAYA (Drug) $24.47
- Oxervate (Drug) $21.83
- VYZULTA (Drug) $11.07
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.